Therapeutic Advances in Rare Disease

Impact Factor: 1.6

Editor-In-Chief: Tiina Urv

Discipline: Clinical Medicine

Description:

Journal HighlightsLaunched in 2020Gold open access journal – all articles are made freely available online immediately upon publicationRigorous peer reviewThe article processing charge (APC) is currently discounted to a rate of $1,500 USDReaches a broad, multidisciplinary audienceTherapeutic Advances in Rare Disease (TAIRD) is a peer-reviewed open access journal which focuses on the highest quality research, reviews and scholarly comment on pioneering efforts and innovative studies across all rare diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers, providing an online forum for publishing the highest quality articles in this area. Please see the Aims and Scope tab for further information.Diversity, Equity and Inclusion StatementTherapeutic Advances in Rare Disease (TAIRD) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the rare disease community.Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms. Submission informationSubmit your manuscript today at http://mc.manuscriptcentral.com/taird.Please see the Submission Guidelines tab for more information on how to submit your article to the journal.Open access informationThe article processing charge (APC) is $3,000 USD, currently discounted to a rate of $1,500 USD. The article processing charge for a Plain Language Summary of Publication is $5,000 USD.ContactPlease direct any queries to TARareDisease@sagepub.com.